

c) REMARKS

The claims are 21-34, with claims 21, 22, 33 and 34 being independent claims. Claims 21 and 22 have been amended to delete compounds (CT-1) and (CT-3). Claims 33 and 34 have been amended to delete compounds (CT-1), (CT-3), (P-1), (P-6), (P-7), (P-8), (P-15), Pd(OAc)₂ and PdCl₂.

The deletion of (P-1), (P-6), (P-7), (P-8), (P-15), Pd(OAc)₂ and PdCl₂ from claims 33 and 34 serves to identify the specific compounds used in the synthesis of (CT-8). See Synthesis Examples 7 and 8.

Claims 21-34 stand rejected under 35 U.S.C. § 103(a), as being allegedly obvious from U.S. Patent No. 5,430,526 (Ohkubo), combined with JP '180 and Applicants' alleged admission. Claims 21-34 stand rejected under 35 U.S.C. § 103(a), as being allegedly obvious from Ohkubo, combined with U.S. Patent No. 5,495,049 (Nukada). The grounds of rejection are respectfully traversed.


The Examiner has acknowledged that Ohkubo does not disclose or suggest the photosensitive member recited in the present claims. However, the Examiner has alleged that JP '180 discloses an electrophotographic photosensitive member comprising a triarylamine having the same formula as compound CT-3 recited in the instant independent claims 21, 22, 33 and 34. Also, while the Examiner acknowledged that JP '180 does not make its triarylamine by the instant method, the Examiner stated that this triarylamine compound has the same formula as CT-3 and is used for the same purpose. The Examiner has also alleged that Nukada's compound CT-13 is the same as compound CT-1 recited in claims 21, 22, 33 and 34. The Examiner noted that Nukada does not make its compound CT-13 by the claimed synthesis.

While Applicants disagree with the Examiner that the JP '180 and Nukada compounds are identical to CT-1 and CT-3, solely to expedite prosecution and without acquiescing to the propriety of the rejections, compounds (CT-1) and (CT-3) have been deleted from the pending claims. Therefore, the claims are clearly patentable over Ohkubo, JP '180 and Nukada, whether these documents are considered alone or in any combination.

Wherefore, Applicants respectfully request that the outstanding final rejection be withdrawn, the claims allowed and that the subject application be passed to issue.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212)218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Peter Saxon
Attorney for Applicants

Registration No. 24947

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200